Zacks Research Has Positive View of OPKO Health Q3 Earnings

Key Points

• Zacks Research raised its Q3 2026 EPS estimate for OPKO Health to a loss of $0.06 per share from a previous estimate of $0.07, while projecting a full-year 2026 loss of $0.22 per share.
• OPKO’s latest quarterly results exceeded expectations, with a $0.01-per-share loss versus the consensus loss estimate of $0.08 and revenue of $163.58 million, up 4.3% year over year.
• Analyst sentiment remains mixed, resulting in a consensus “Hold” rating and a $1.55 price target; institutional investors own approximately 64.63% of the company.

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities researchers at Zacks Research increased their Q3 2026 earnings estimates for OPKO Health in a research report issued on Monday, August 17th. Zacks Research analyst Team now expects that the biotechnology company will earn ($0.06) per share for the quarter, up from their previous estimate of ($0.07). The consensus estimate for OPKO Health's current full-year earnings is ($0.24) per share. Zacks Research also issued estimates for OPKO Health's FY2026 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.28) EPS, Q1 2028 earnings at ($0.06) EPS, Q2 2028 earnings at ($0.06) EPS and FY2028 earnings at ($0.23) EPS.

OPK has been the topic of several other research reports. Wall Street Zen upgraded shares of OPKO Health from a "sell" rating to a "hold" rating in a report on Saturday, June 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of OPKO Health in a research note on Thursday, August 13th. HC Wainwright reissued a "buy" rating on shares of OPKO Health in a research report on Wednesday, July 29th. Finally, Barrington Research downgraded shares of OPKO Health from an "outperform" rating to a "market perform" rating in a research note on Wednesday, April 29th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $1.55.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.36 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93. OPKO Health has a 1-year low of $0.98 and a 1-year high of $1.73. The firm has a market capitalization of $1.02 billion, a P/E ratio of -15.11 and a beta of 1.51. The business's 50-day simple moving average is $1.37 and its 200-day simple moving average is $1.27.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.07. The business had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The business's quarterly revenue was up 4.3% on a year-over-year basis. During the same period last year, the company posted ($0.19) EPS.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OPK. OP Asset Management Ltd bought a new stake in shares of OPKO Health in the 1st quarter worth about $1,257,000. First Trust Advisors LP bought a new position in shares of OPKO Health during the first quarter worth about $570,000. UBS Group AG grew its stake in OPKO Health by 12.1% in the fourth quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company's stock worth $6,745,000 after purchasing an additional 577,248 shares in the last quarter. Comerica Bank raised its stake in OPKO Health by 7.1% during the fourth quarter. Comerica Bank now owns 120,000 shares of the biotechnology company's stock valued at $151,000 after buying an additional 8,000 shares in the last quarter. Finally, State of Wyoming bought a new position in OPKO Health during the 1st quarter worth approximately $190,000. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc NASDAQ: OPK is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source